Abstract
At the end of 2020, a vaccination campaign against COVID-19 was launched. In 2021, legal obligations for health workers, as well as specific regulations for all workers, were introduced. The global SARS-CoV-2 pandemic was followed by epochal changes in life, school, and work habits in Italy. Therefore, the pharmacovigilance work currently being conducted in Italy by the AIFA concerning the recording and analysing of adverse reactions related to the use of vaccines has proved to be very important. The latest report, including a period of 10 months from December 2020 to September 2021, has allowed us to combine the results received so far, and to compare the safety of all vaccines currently available in Italy. The results of this analysis are highly encouraging and reveal the statistical reliability of the safety of the COVID-19 vaccines currently used in Italy. The dissemination of these findings could increase the public’s awareness of vaccines and their ability to make free and informed choices concerning vaccination. The potential increase in the Italian population’s adherence to the vaccination campaign could ultimately be a decisive factor in achieving herd immunity and the final resolution of the pandemic.
Highlights
Received: 12 December 2021In December 2019, a new strain of the SARS-CoV species had its first outbreak in the Chinese province of Hubei [1] and soon spread rapidly worldwide, causing the WorldHealth Organization (WHO) to declare pandemic status in March 2020 [2]
Based on the data contained in the Italian AIFA reports, it is possible to state that the current trend of reports of adverse events related to vaccination against COVID-19 in
Further months of observation appear necessary in order to make a final judgment on the safety of anti-COVID-19 vaccination. At such an exceptional and delicate historical moment, the prompt availability of vaccines for the fight against the SARS-CoV-2 pandemic has necessitated an accurate study of their actual safety
Summary
In December 2019, a new strain of the SARS-CoV species had its first outbreak in the Chinese province of Hubei [1] and soon spread rapidly worldwide, causing the World. It is interesting to note that in all age groups, while there is substantial equivalence between the two sexes as regards the number of doses administered, the majority of reactions affected female subjects (71%) (Figure 2). Estimate the numbers adversesulla events per 100,000dei doses administered the period 27 D ber 2020–26 September 2021 Analysis of the data shows that most adverse reactions occur in the short term: 48% of reports are made within the first It is interesting analyze the within time latency are carried outAnalysis after oneof week of administration.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
